Drug intelligence / Profile preview

GSB D100

Development stage: Preclinical
Lead developer: Greenstone Biosciences

Overview

GSB D100 is an investigational drug candidate being developed by GreenStone Biosciences for fibrotic indications. As of August 2024, it is in the IND-enabling stage, which means it has not yet entered clinical trials but is undergoing studies required to support an Investigational New Drug (IND) application. The specific mechanism of action, molecular modality, and detailed pharmacological profile have not been publicly disclosed. Its development focuses on treating diseases characterized by fibrosis, a pathological process involving excessive tissue scarring and extracellular matrix deposition.

Beyond the preview

Go deeper on GSB D100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSB D100.

Explore the full profile